Aflibercept: A Comprehensive Monograph on a Dual-Indication VEGF-Trap Fusion Protein

Executive Summary

Aflibercept represents a significant achievement in rational drug design, a recombinant fusion protein engineered to act as a high-affinity "VEGF Trap." This unique molecular architecture has enabled it to forge two distinct, and starkly contrasting, therapeutic identities. As the ophthalmic formulation, Eylea®, it has become a blockbuster therapy, transforming the standard of care for a range of neovascular retinal diseases, including neovascular (wet) age-related macular degeneration (nAMD) and diabetic eye diseases. Its primary clinical advantage lies in its potent and sustained inhibition of the VEGF pathway, which translates into less frequent intravitreal injections compared to its predecessors, thereby reducing the treatment burden for patients with chronic conditions. The development of a higher-dose formulation, Eylea HD®, further extends this benefit, pushing dosing intervals to four months or longer for many patients.

Conversely, the systemic formulation, Zaltrap®, has carved out a much smaller niche in oncology. Approved for second-line treatment of metastatic colorectal cancer (mCRC), it demonstrated a modest but statistically significant survival benefit in patients who had progressed on prior therapy. However, the high systemic doses required to achieve this effect unmask a formidable toxicity profile, including boxed warnings for severe hemorrhage, gastrointestinal perforation, and impaired wound healing. This challenging safety profile has limited its broader application and stands in sharp contrast to the generally well-tolerated local administration of Eylea®.

Aflibercept's journey from a single molecule to two disparate clinical products provides a compelling case study in the principles of pharmacokinetics and therapeutic index. The low systemic exposure following intravitreal injection is sufficient to suppress a biomarker (plasma VEGF) but remains below the threshold required to induce the severe systemic adverse events associated with the intravenous formulation. Now, as the original Eylea® formulation faces the end of its market exclusivity, the Aflibercept franchise is at a critical inflection point. The approval of the first interchangeable biosimilars in 2024 signals the dawn of a new competitive era. The strategic landscape is now defined by the interplay between the originator's defense strategy, centered on converting the market to the longer-acting, patent-protected Eylea HD®, and the impending market entry of lower-cost biosimilars, which promises to reshape the economic and clinical calculus for treating retinal diseases worldwide.

Introduction: Aflibercept as a Paradigm of Targeted Biologic Therapy

The development of therapies targeting the Vascular Endothelial Growth Factor (VEGF) pathway marks a pivotal moment in the treatment of diseases characterized by pathological angiogenesis, the abnormal growth of new blood vessels. VEGF, along with related proteins like Placental Growth Factor (PlGF), are key signaling molecules that promote the proliferation and migration of endothelial cells and increase vascular permeability, or leakage.[1] In conditions such as neovascular (wet) age-related macular degeneration (nAMD) and metastatic cancer, the overexpression of these factors drives disease progression, leading to vision loss or tumor growth, respectively.[2]

Within this therapeutic class, Aflibercept distinguishes itself not as a conventional monoclonal antibody but as a novel recombinant fusion protein.[1] It is engineered to function as a "soluble decoy receptor" or, more evocatively, a "VEGF Trap".[3] This unique structure allows it to bind and neutralize multiple key angiogenic factors with exceptionally high affinity, effectively sequestering them and preventing their interaction with native cell-surface receptors.[3]

This molecular platform has been leveraged to create two distinct therapeutic products for disparate medical fields. For ophthalmology, a low-dose formulation administered via intravitreal injection is marketed as Eylea® and Eylea HD®, targeting a host of retinal vascular diseases.[6] For oncology, a high-dose formulation for intravenous infusion, known as Zaltrap® (with the non-proprietary name ziv-aflibercept to prevent medication errors), is used in combination with chemotherapy for a specific subset of patients with metastatic colorectal cancer (mCRC).[5] This dual-indication strategy, originating from a single engineered molecule, underscores the central role of VEGF in diverse pathologies and highlights the critical importance of formulation and delivery route in defining a drug's clinical utility and safety profile.

Table 1: Aflibercept Identifiers and Commercial Formulations

Identifier/Name	Detail	Source(s)
Generic Name	Aflibercept	1
Systemic Generic Name	Ziv-Aflibercept	5
DrugBank ID	DB08885	1
CAS Number	862111-32-8	6
Drug Type	Biotech, Recombinant Fusion Protein	1
Ophthalmic Brand Names	Eylea®, Eylea HD®, Yesafili®, Opuviz®, Pavblu®, Ahzantive®, Enzeevu®	1
Oncology Brand Name	Zaltrap®	1
Originator/Developers	Regeneron Pharmaceuticals, Bayer, Sanofi	5

Molecular Profile and Structural Engineering

Aflibercept's design is a showcase of rational protein engineering, meticulously constructed to optimize its function as a high-potency antagonist of the VEGF pathway. It is a fully human, dimeric glycoprotein with a complex architecture that sets it apart from monoclonal antibody-based therapies.[2]

Recombinant Fusion Protein Architecture

The fundamental structure of Aflibercept consists of two identical polypeptide chains covalently linked by disulfide bridges to form a dimer.[20] Each chain is a fusion protein created by joining specific, functional domains from two different human VEGF receptors to the constant region (Fc) of human immunoglobulin G1 (IgG1).[5] The engineered components are:

1. The second immunoglobulin (Ig) domain of human VEGF receptor 1 (VEGFR1): This domain is a primary binding site for VEGF-A and PlGF.[7]
2. The third immunoglobulin (Ig) domain of human VEGF receptor 2 (VEGFR2): This domain is critical for high-affinity binding to VEGF-A.[7]
3. The Fc portion of human IgG1: This segment provides structural stability, facilitates dimerization, and is thought to extend the molecule's half-life through interaction with the neonatal Fc receptor (FcRn), which rescues it from catabolism.[20]

The selection of these specific receptor domains was a deliberate engineering choice. By combining the most potent binding elements from both VEGFR1 and VEGFR2, the resulting fusion protein acts as a "super-receptor" with binding characteristics superior to either native receptor alone.[3] This design creates a molecule with an engineered advantage, leading to a higher binding affinity and a broader binding profile that encompasses not only VEGF-A but also related family members VEGF-B and PlGF.[1]

Molecular Characteristics

Aflibercept's molecular formula is C4318​H6788​N1164​O1304​S32​.[1] The protein portion of the molecule has a molecular weight of approximately 96.9 to 97 kDa.[2] However, the molecule undergoes significant post-translational modification in the form of glycosylation, which accounts for approximately 15% of its total mass. This brings the final molecular weight of the glycosylated dimer to approximately 115 kDa.[1] In its therapeutic form, it is supplied as a clear, colorless to pale yellow, iso-osmotic liquid solution for injection.[7]

Glycosylation and Production

Aflibercept is produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) K1 cells, a standard mammalian cell line for manufacturing complex therapeutic proteins.[7] The primary amino acid sequence predicts five potential N-glycosylation sites on each of the two polypeptide chains. All five of these sites can be occupied by complex carbohydrate structures, which exhibit a degree of heterogeneity, including variations in terminal sialic acid residues.[1] This glycosylation is crucial for the proper folding, stability, and solubility of the protein.

Structural Comparison to Competitors

The structural ingenuity of Aflibercept becomes clear when contrasted with its main competitors in the anti-VEGF space:

• Bevacizumab (Avastin®) is a full-length, bivalent humanized monoclonal antibody with a molecular weight of 149 kDa. It targets all isoforms of VEGF-A.[23] Its large size and Fc region contribute to a long systemic half-life.
• Ranibizumab (Lucentis®) is a much smaller molecule, an antibody fragment (Fab) with a molecular weight of only 48 kDa.[23] It lacks an Fc region and is therefore cleared more rapidly from systemic circulation. It also targets VEGF-A.
• Aflibercept (Eylea®/Zaltrap®), at 115 kDa, sits between these two in size. Its unique fusion protein structure, combining receptor domains with an Fc backbone, gives it a distinct set of properties, including a broader binding profile and a "trap" mechanism of action that differentiates it functionally from the direct antibody-based blockade of its competitors.[7]

Pharmacodynamics: The High-Affinity "VEGF Trap" Mechanism

The therapeutic efficacy of Aflibercept is rooted in its potent and unique pharmacodynamic properties. It functions as a decoy receptor, effectively intercepting and neutralizing key molecular drivers of angiogenesis and vascular permeability before they can initiate their pathological effects.[1]

Decoy Receptor Mechanism of Action

Aflibercept acts as a soluble, high-affinity decoy receptor that binds to multiple members of the VEGF family, including all isoforms of VEGF-A, VEGF-B, and PlGF.[1] By sequestering these ligands in the extracellular space, Aflibercept prevents them from binding to and activating their natural, cell-surface receptors, VEGFR-1 and VEGFR-2.[1] Because Aflibercept lacks the transmembrane and intracellular signaling domains of the native receptors, its binding to these growth factors does not trigger any downstream cellular response. Instead, it renders the growth factors inert.[1] This competitive inhibition effectively shuts down the signaling cascade responsible for endothelial cell proliferation, migration, and fenestration, thereby suppressing neovascularization and reducing the vascular leakage that characterizes the diseases it is approved to treat.[1]

Binding Affinity and Potency

A key feature of Aflibercept's design is its exceptionally high binding affinity, which surpasses that of the native VEGF receptors and other anti-VEGF agents.[3] This potency is quantified by the equilibrium dissociation constant (

KD​), where a lower value indicates tighter binding.

• Aflibercept binds to human VEGF-A165 with a KD​ of approximately 0.5 pM.[1] This is orders of magnitude stronger than the binding affinity of ranibizumab ( KD​ ~21 pM) and bevacizumab (KD​ ~35 pM) for the same ligand.[7]
• Its affinity for VEGF-A is also substantially higher than that of the native receptors themselves (VEGFR1 KD​ ~9 pM; VEGFR2 KD​ ~89 pM).[3]
• Beyond VEGF-A, it also effectively binds VEGF-B (KD​ ~1.9 pM) and PlGF-2 (KD​ ~39 pM), giving it a broader spectrum of activity than agents that target only VEGF-A.[1]

The "VEGF Trap" Concept

The term "VEGF Trap" aptly describes Aflibercept's mechanism. It binds to the VEGF-A dimer in a unique 1:1 stoichiometry, engaging both sides of the growth factor to form an extremely stable, inert complex.[3] This complex has a very slow dissociation rate (off-rate), meaning that once Aflibercept has "trapped" a VEGF molecule, it is very unlikely to release it.[23]

This combination of extremely high binding affinity and a slow dissociation rate is the core pharmacodynamic principle that underpins Aflibercept's clinical profile, particularly its extended duration of action. The clinical goal for chronic eye diseases like nAMD is to reduce the frequency of intravitreal injections to ease the burden on patients and healthcare systems. While one approach is to increase a drug's pharmacokinetic half-life (i.e., how long it stays in the eye), Aflibercept's design achieves a similar outcome through a pharmacodynamic approach. By engineering a molecule that binds its target with such high affinity and tenacity, the biological effect of target suppression is maintained long after the concentration of free, unbound Aflibercept in the vitreous has declined. Even as the body clears the unbound drug, the VEGF that has already been bound remains trapped and neutralized. This sustained target suppression is the true driver of its long-acting clinical profile and was the foundational principle that led to the successful development of less frequent dosing regimens, culminating in the 12- and 16-week intervals achievable with Eylea HD.[30]

Pharmacokinetic Profile: A Tale of Two Formulations

The pharmacokinetic behavior of Aflibercept is fundamentally dictated by its route of administration, leading to two vastly different profiles for the intravitreal (Eylea®) and intravenous (Zaltrap®) formulations. This dichotomy is central to understanding the drug's distinct efficacy and safety in ophthalmology versus oncology.

A. Intravitreal Administration (Eylea®)

When administered directly into the vitreous cavity of the eye, the eye effectively acts as a drug reservoir, leading to high local concentrations and a slow, limited release into the systemic circulation.

• Absorption and Systemic Exposure: Following a standard 2 mg intravitreal injection, Aflibercept is slowly absorbed into the systemic circulation. It reaches very low peak plasma concentrations (Cmax) of 0.02 to 0.05 mcg/mL, which are typically observed 1 to 3 days post-injection.[1] Due to its clearance from the bloodstream, the concentration of free, active Aflibercept in the plasma is generally undetectable by two weeks after the dose.[1] The higher 8 mg dose of Eylea HD results in a mean Cmax of 0.30 mg/L, with minimal accumulation observed after initial monthly doses.[1]
• Systemic VEGF Suppression: A key pharmacokinetic paradox is that despite these low systemic levels of free drug, intravitreal Aflibercept leads to a rapid, profound, and sustained suppression of free VEGF in the plasma.[27] This occurs because the small amount of Aflibercept that enters the circulation is highly efficient at binding and neutralizing systemic VEGF, forming the stable, inactive Aflibercept:VEGF complex.[23] This demonstrates a measurable systemic pharmacodynamic effect from a local administration route.
• Intraocular Half-Life: Precisely determining the half-life of Aflibercept within the human eye is challenging and has yielded varied results depending on the methodology.
• Studies in animal models (rabbits and monkeys) reported vitreous half-lives ranging from 2.4 to 4.6 days.[31]
• Direct measurement in human aqueous humor (a surrogate for the vitreous) calculated a half-life of approximately 2.9 days.[32]
• Population pharmacokinetic modeling, which uses systemic drug concentrations to extrapolate the intraocular profile, estimated a longer vitreous half-life of approximately 7.1 to 9 days.[1] This discrepancy highlights the complexity of measuring local drug disposition.

B. Intravenous Administration (Zaltrap®)

When administered systemically as an intravenous infusion for cancer treatment, the pharmacokinetic profile is entirely different.

• Distribution and Clearance: Following a 4 mg/kg IV infusion, Zaltrap distributes throughout the body with a volume of distribution of approximately 7 liters.[1] The clearance of free ziv-aflibercept from the plasma is estimated to be 0.88 L/day.[1]
• Half-Life: The systemic elimination half-life of free ziv-aflibercept is approximately 6 days (range 4-7 days), significantly longer than the transient appearance of free drug after an intravitreal dose.[1]

Metabolism and Excretion

As a large protein-based therapeutic, Aflibercept is not metabolized by the cytochrome P450 system. It is expected to be broken down into smaller peptides and amino acids through proteolysis, a general process for protein catabolism. Additionally, its primary clearance mechanism involves target-mediated disposition, where it is cleared from circulation after binding to its VEGF targets.[1]

The divergent pharmacokinetic profiles of Eylea® and Zaltrap® are critical to their clinical use. The local, depot-like nature of intravitreal injection ensures that high, therapeutic concentrations are achieved in the target organ (the eye) while minimizing systemic exposure to the active drug. The systemic effect that is observed—the suppression of plasma VEGF—appears to exist within a therapeutic window. The level of systemic exposure is sufficient to affect this biomarker but is too low to trigger the overt, dose-limiting toxicities (such as severe hypertension, hemorrhage, or GI perforation) that are seen with the much higher and sustained systemic concentrations achieved with intravenous Zaltrap®. This provides a strong scientific rationale for the favorable systemic safety profile of Eylea® in long-term ophthalmic use.[23]

Clinical Efficacy in Ophthalmic Disorders (Eylea® & Eylea HD®)

The clinical development program for Aflibercept in ophthalmology has been remarkably successful, establishing its efficacy across a broad spectrum of neovascular retinal diseases and positioning Eylea® as a leading therapy worldwide. Its success is built on a foundation of robust clinical trial data demonstrating strong visual acuity gains coupled with a reduced treatment burden.

A. Neovascular Age-Related Macular Degeneration (nAMD)

nAMD was the first and most significant indication for Eylea®, with pivotal trials designed to challenge the existing standard of care.

• Pivotal VIEW 1 & 2 Trials: These two large, parallel, multinational Phase III trials were the cornerstone of Eylea's initial FDA approval.[33] The trials were designed as non-inferiority studies comparing different Aflibercept dosing regimens against the then-market leader, monthly ranibizumab (Lucentis®).[34]
• Design: Patients were randomized to receive Aflibercept 2 mg every 4 weeks (2q4), Aflibercept 0.5 mg every 4 weeks (0.5q4), Aflibercept 2 mg every 8 weeks after three initial monthly loading doses (2q8), or ranibizumab 0.5 mg every 4 weeks (Rq4).[35]
• Primary Endpoint: The primary endpoint was the proportion of patients who maintained vision (defined as losing fewer than 15 letters on the ETDRS eye chart) at 52 weeks.[35]
• Key Outcome: The Aflibercept 2q8 regimen proved to be non-inferior to the monthly ranibizumab regimen (95.1% vs. 94.4% of patients maintained vision).[34] This result was transformative, as it demonstrated that Aflibercept could achieve clinically equivalent visual outcomes to the standard of care while requiring only half the number of injections during the maintenance phase (every 8 weeks vs. every 4 weeks). This significant reduction in treatment burden became Eylea's core value proposition.[36]
• High-Dose Aflibercept (Eylea HD® 8 mg) and the PULSAR Trial: To further improve upon the dosing interval, Regeneron developed a high-dose formulation.
• Rationale: The goal was to leverage Aflibercept's potent, long-acting mechanism to extend the time between injections even further, potentially to 12 or 16 weeks, or longer.
• Outcomes: The pivotal PULSAR trial successfully demonstrated that Eylea HD (8 mg) dosed every 12 weeks or every 16 weeks was non-inferior to Eylea (2 mg) dosed every 8 weeks in terms of mean change in best-corrected visual acuity (BCVA) at 48 weeks.[38] Follow-up data at three years showed that these vision gains were durable, with a large majority of patients able to maintain dosing intervals of three months or longer, and a substantial portion extending to four or even five months between injections.[30]

B. Diabetic Eye Disease (Diabetic Macular Edema and Diabetic Retinopathy)

Aflibercept has also proven to be a highly effective treatment for vision-threatening complications of diabetes.

• Pivotal VISTA & VIVID Trials: The VISTA trial established the superiority of Eylea® over the prior standard of care, macular laser photocoagulation, for DME. After two years of treatment, patients receiving Eylea® (dosed either monthly or every two months after a loading phase) experienced a mean BCVA gain of over +11 letters, compared to just +0.9 letters in the laser control group.[39]
• Comparative Effectiveness (DRCR.net Protocol T): This landmark, government-funded, head-to-head clinical trial provided a direct comparison of the three most commonly used anti-VEGF agents for DME: Aflibercept, bevacizumab, and ranibizumab.[40]
• One-Year Results: The results were nuanced and depended on the patient's baseline vision. For patients with mild vision loss (20/32 to 20/40), all three drugs produced similar improvements in vision. However, for patients with worse baseline vision (20/50 or worse), Aflibercept was statistically superior to both bevacizumab and ranibizumab in improving vision.[40]
• Two-Year Results: At the two-year mark, the visual acuity outcomes had evolved. Aflibercept maintained its superiority over bevacizumab in the worse-vision subgroup, but its advantage over ranibizumab was no longer statistically significant. In the better-vision subgroup, all three drugs remained comparable.[40] This trial provided invaluable data for clinicians, suggesting that a stratified treatment approach based on initial visual acuity may be most appropriate for DME.

C. Macular Edema Following Retinal Vein Occlusion (RVO)

Aflibercept is approved for treating macular edema secondary to both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Its approval was based on data from pivotal trials such as COPERNICUS and GALILEO, which demonstrated that monthly 2 mg injections of Eylea® led to rapid and significant improvements in vision compared to sham injections.[36] The standard recommended dosing for this indication is a 2 mg injection every four weeks.[36]

D. Retinopathy of Prematurity (ROP)

In a significant expansion of its label, Eylea® was approved by the FDA in February 2023 for the treatment of ROP in preterm infants.[1] Administered at a much lower dose of 0.4 mg, it became the first and only FDA-approved pharmacological treatment for this condition, which can lead to blindness in premature babies.[11] This approval addressed a critical unmet need and provided an alternative to laser surgery for these vulnerable patients.[41]

Table 2: Summary of Key Phase III Trials for Ophthalmic Indications

Trial Name	Indication	Comparator(s)	Primary Endpoint (at 1 year)	Key Efficacy Result	Source(s)
VIEW 1 & 2	nAMD	Ranibizumab (0.5 mg monthly)	Non-inferiority in proportion of patients maintaining vision (<15 letter loss)	Aflibercept 2 mg every 8 weeks was non-inferior to monthly ranibizumab.	34
PULSAR	nAMD	Aflibercept (2 mg every 8 weeks)	Non-inferiority in mean change in BCVA at 48 weeks	Aflibercept 8 mg every 12 or 16 weeks was non-inferior to Aflibercept 2 mg every 8 weeks.	30
VISTA	DME	Macular Laser Photocoagulation	Mean change in BCVA from baseline	Aflibercept groups gained ~+11-12 letters vs. ~+0.2 letters for laser at 1 year.	39
Protocol T	DME	Bevacizumab, Ranibizumab	Mean change in BCVA from baseline	Aflibercept was superior to both for baseline VA ≤20/50; all 3 were similar for baseline VA ≥20/40.	40
COPERNICUS	Macular Edema (CRVO)	Sham Injection	Proportion of patients gaining ≥15 letters in BCVA at 24 weeks	56% of Aflibercept patients gained ≥15 letters vs. 12% of sham patients.	39

Clinical Efficacy in Oncology (Zaltrap®)

In stark contrast to its widespread success in ophthalmology, the clinical journey of Aflibercept in oncology has been one of narrow success amidst broader setbacks. Its development culminated in a single approved indication for the systemic formulation, Zaltrap®.

A. Metastatic Colorectal Cancer (mCRC)

The approval of Zaltrap® is based entirely on the results of one large, international Phase III study.

• Pivotal VELOUR Trial: This randomized, double-blind, placebo-controlled trial was designed to evaluate Zaltrap® in a specific, heavily pre-treated patient population: individuals with mCRC whose disease had progressed during or after treatment with an oxaliplatin-containing chemotherapy regimen.[43]
• Design: The trial randomized 1,226 patients to receive either Zaltrap® (at a dose of 4 mg/kg intravenously every two weeks) in combination with the FOLFIRI chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan), or a placebo in combination with FOLFIRI.[44]
• Primary Endpoint (Overall Survival): The VELOUR trial successfully met its primary endpoint. The addition of Zaltrap® to FOLFIRI resulted in a statistically significant, though modest, improvement in median overall survival (OS). Patients in the Zaltrap® arm had a median OS of 13.50 months, compared to 12.06 months for patients in the placebo arm. This represented a hazard ratio (HR) of 0.817, corresponding to an 18.3% reduction in the risk of death (p=0.0032).[43]
• Secondary Endpoint (Progression-Free Survival): The trial also demonstrated a significant benefit in progression-free survival (PFS). Median PFS was 6.90 months for the Zaltrap® group versus 4.67 months for the placebo group (HR=0.758, p=0.00007).[46]
• Subgroup Analyses: A critical finding from prespecified subgroup analyses was that the survival benefit of Zaltrap® was maintained in patients regardless of whether they had received prior treatment with bevacizumab, another anti-VEGF therapy.[44] This suggested that Zaltrap® could offer a benefit even after the failure of a different VEGF inhibitor, possibly due to its broader binding profile that includes PlGF and VEGF-B.

B. Investigational History and Discontinued Trials

The initial development strategy for Aflibercept in oncology was ambitious, with a broad program investigating its use in several advanced solid tumors.[50] Phase III trials were conducted in non-small cell lung cancer, hormone-refractory prostate cancer (the VENICE trial), and pancreatic cancer.[51] However, these trials ultimately failed to meet their primary endpoints for improving overall survival, leading to the discontinuation of Aflibercept's development for these indications.[51]

The divergent outcomes between the VELOUR trial and other oncology studies frame the story of Zaltrap®. The initial hypothesis that a more potent and broader-spectrum VEGF trap would be a superior anti-cancer agent across multiple tumor types did not bear out. The modest survival benefit observed in the VELOUR trial (a 1.44-month improvement in median OS) was accompanied by a significant increase in systemic toxicity, including several boxed warnings.[45] This narrow risk/benefit ratio likely proved unfavorable in other cancer types or in combination with different chemotherapy backbones. The success in mCRC suggests that the unique biology of disease progression after oxaliplatin and the potential role of PlGF or VEGF-B in that specific context may have created a therapeutic niche for Zaltrap®. Ultimately, Zaltrap® established itself not as a broad-spectrum anti-angiogenic agent like bevacizumab, but as a specialized, second-line therapy for a well-defined patient population, a reality that sharply contrasts with Eylea's blockbuster status.

Table 3: Summary of the VELOUR Phase III Trial for Metastatic Colorectal Cancer

Parameter	Details	Source(s)
Trial Name	VELOUR (NCT00561470)	43
Indication	Metastatic Colorectal Cancer (mCRC) after progression on an oxaliplatin-containing regimen	44
Phase	III	45
Number of Patients	1,226	43
Treatment Arms	1. Zaltrap® (4 mg/kg IV q2w) + FOLFIRI 2. Placebo + FOLFIRI	44
Primary Endpoint	Overall Survival (OS)	45
Median OS	13.50 months (Zaltrap® arm) vs. 12.06 months (Placebo arm)	43
OS Hazard Ratio	0.817 (95.34% CI: 0.713 to 0.937)	45
OS p-value	p=0.0032	43
Median PFS	6.90 months (Zaltrap® arm) vs. 4.67 months (Placebo arm)	46
PFS Hazard Ratio	0.758 (95% CI: 0.661 to 0.869)	48
PFS p-value	p=0.00007	46

Comparative Analysis and Economic Considerations

The clinical landscape for neovascular retinal diseases is dominated by three anti-VEGF agents: Aflibercept, ranibizumab, and bevacizumab. The choice among them is a complex decision for clinicians and healthcare systems, involving a nuanced assessment of molecular differences, clinical efficacy, treatment burden, and cost.

A. Aflibercept vs. Ranibizumab vs. Bevacizumab: A Multi-faceted Comparison

These three drugs differ fundamentally in their structure, mechanism, and pharmacokinetic properties, which in turn influences their clinical profiles.

• Molecular Structure: As previously detailed, the agents represent three distinct classes of biologics: Aflibercept is a 115 kDa fusion protein, bevacizumab is a 149 kDa full monoclonal antibody, and ranibizumab is a 48 kDa antibody fragment (Fab).[7]
• Mechanism and Target Profile: Aflibercept acts as a "VEGF Trap," binding not only to all isoforms of VEGF-A but also to VEGF-B and PlGF. In contrast, both ranibizumab and bevacizumab are more specific, targeting only VEGF-A.[1] This broader target engagement is a theoretical advantage for Aflibercept.
• Binding Affinity: Aflibercept demonstrates a markedly higher binding affinity for VEGF-A compared to both ranibizumab and bevacizumab, as evidenced by its sub-picomolar dissociation constant (KD​).[3]
• Dosing Frequency: The combination of high affinity and slow dissociation translates into Aflibercept's key clinical advantage: a longer duration of action that permits less frequent maintenance dosing. Standard Eylea® is typically dosed every 8 weeks in nAMD after loading doses, while Eylea HD® can extend this to 12, 16, or more weeks. This compares favorably to the standard monthly dosing often required for ranibizumab and bevacizumab to maintain efficacy.[30]
• Clinical Efficacy: Head-to-head trials have revealed a nuanced efficacy picture. The DRCR.net Protocol T trial in DME found that Aflibercept provided superior vision gains over its competitors in patients with significant baseline vision loss at one year, though this advantage over ranibizumab diminished by year two.[40] In patients with better baseline vision, the three drugs were largely equivalent. This suggests that while Aflibercept may offer an advantage in more severe disease, the clinical benefit may not be universally superior across all patient populations.

Table 4: Comparative Molecular and Pharmacokinetic Properties of Aflibercept, Ranibizumab, and Bevacizumab

Parameter	Aflibercept (Eylea®)	Ranibizumab (Lucentis®)	Bevacizumab (Avastin®)
Molecular Structure	Recombinant Fusion Protein	Antibody Fragment (Fab)	Full Monoclonal Antibody (IgG1)
Molecular Weight	~115 kDa	~48 kDa	~149 kDa
Target(s)	VEGF-A, VEGF-B, PlGF	VEGF-A	VEGF-A
Binding Affinity (Kd for VEGF-A)	~0.5 pM	~21 pM	~35 pM
Systemic Half-Life	~6 days (IV), transient after IVT	~2 hours	~20 days
Estimated Vitreous Half-Life	~7-9 days	~7-9 days	~10 days
Typical nAMD Dosing (Maintenance)	Every 8-16 weeks	Every 4 weeks	Every 4-6 weeks (off-label)

Sources: [1]

B. Cost-Effectiveness Analysis

The economic evaluation of these therapies is heavily influenced by their disparate costs.

• The Bevacizumab Dilemma: Bevacizumab, while used off-label for ophthalmic indications, is available at a fraction of the cost of the approved agents. Compounded from the oncology formulation, an injection can cost as little as £28-£50, compared to list prices of £551 for ranibizumab and £816 for Aflibercept in the UK.[55] Consequently, numerous cost-effectiveness analyses have consistently concluded that bevacizumab is by far the most cost-effective option for treating retinal diseases like nAMD and RVO-related macular edema.[55] Even when it does not meet strict non-inferiority criteria for visual acuity, the similar quality-of-life outcomes combined with massive cost savings make it the dominant choice from a health economics perspective.[55]
• Aflibercept vs. Ranibizumab: When comparing the two premium, approved drugs, the analyses are more complex. The higher per-injection cost of Aflibercept is intended to be offset by the need for fewer injections and monitoring visits over time. However, multiple studies, including an analysis based on the 2-year Protocol T data, have found that Aflibercept is generally not cost-effective compared to ranibizumab.[58] The total 2-year costs for Aflibercept were found to be substantially higher ($44,423 vs $34,529), while the gain in quality-adjusted life-years (QALYs) was marginal. The resulting incremental cost-effectiveness ratios (ICERs) were often in the hundreds of thousands of dollars per QALY, far exceeding standard willingness-to-pay thresholds.[59]
• Impact of Biosimilars: The entire economic landscape is poised for a dramatic shift with the arrival of biosimilars for all three agents. The introduction of lower-cost alternatives will intensify price competition and will likely render many of the existing cost-effectiveness models obsolete. The availability of biosimilar bevacizumab, ranibizumab, and Aflibercept will provide more options for payers and clinicians, and the ultimate treatment choice may depend more on negotiated prices, physician experience, and specific patient needs rather than the large list price differentials that have defined the market for the past decade.

Comprehensive Safety and Risk Management Profile

The safety profile of Aflibercept is a tale of two drugs, with the local ophthalmic formulation having a well-established and manageable risk profile, while the systemic oncology formulation carries severe, life-threatening toxicities that necessitate stringent warnings and careful patient management.

A. Ophthalmic Formulations (Eylea® & Eylea HD®)

The risks associated with Eylea® are primarily related to the intravitreal injection procedure itself and the local effects of VEGF inhibition in the eye.

• Contraindications: Eylea® is strictly contraindicated in patients with active ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to Aflibercept or any of its excipients.[26]
• Warnings and Precautions:
• Injection-Related Complications: As with any intravitreal injection, there is a risk of serious complications, including endophthalmitis (a severe infection inside the eye), retinal detachments, and iatrogenic traumatic cataract. These events are rare (<0.1% of injections) but can be vision-threatening. Strict aseptic injection technique is mandatory to minimize these risks.[26]
• Increased Intraocular Pressure (IOP): A transient increase in IOP is commonly observed within 60 minutes of injection due to the volume of fluid introduced into the eye. Sustained IOP elevation has also been reported with repeated dosing. Therefore, IOP must be monitored post-injection.[41]
• Arterial Thromboembolic Events (ATEs): There is a potential risk of ATEs (such as non-fatal stroke or myocardial infarction) following intravitreal use of any VEGF inhibitor. Data from large clinical trials show a low incidence for Eylea® (1.8% - 3.3% through one to two years in nAMD studies), which is comparable to that of ranibizumab.[16]
• Retinal Vasculitis: Rare but serious cases of retinal vasculitis, sometimes with occlusion, have been reported in postmarketing surveillance. This is an inflammatory event that can cause severe vision loss.[38]
• Common Adverse Reactions: The most frequently reported adverse events (affecting ≥5% of patients) are generally mild to moderate and related to the injection or the local effects of the drug. These include conjunctival hemorrhage (bruising on the white of the eye), eye pain, cataract formation or progression, vitreous detachment, vitreous floaters, and increased IOP.[5]

B. Systemic Formulation (Zaltrap®)

The safety profile of Zaltrap®, when administered intravenously at high doses, is dominated by systemic toxicities directly related to widespread VEGF inhibition. Its label includes a prominent Boxed Warning for three potentially fatal complications.

• BOXED WARNING:
• Hemorrhage: Zaltrap® significantly increases the risk of severe and sometimes fatal bleeding, including gastrointestinal hemorrhage. It should not be given to patients with severe active bleeding.[17]
• Gastrointestinal (GI) Perforation: The drug can cause a hole to form in the stomach or intestines, an event that can be fatal. Zaltrap® must be discontinued permanently if this occurs.[17]
• Compromised Wound Healing: Zaltrap® interferes with the body's ability to heal. Treatment must be stopped at least 4 weeks prior to elective surgery and not resumed for at least 4 weeks after major surgery and until the wound is fully healed.[17]
• Other Major Warnings and Precautions: Beyond the boxed warnings, Zaltrap® is associated with a host of other serious risks, including:
• Hypertension: Severe high blood pressure is common and requires active monitoring and management.[17]
• Arterial Thromboembolic Events (ATEs): A higher risk of blood clots in arteries leading to stroke or heart attack.[53]
• Proteinuria: High levels of protein in the urine, which can progress to nephrotic syndrome, a serious kidney disorder.[17]
• Fistula Formation: The development of abnormal passages between internal organs or between an organ and the skin.[17]
• Neutropenia and Severe Diarrhea: Increased risk of low white blood cell counts (leading to infection) and severe, dehydrating diarrhea.[17]
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS): A rare but serious neurological disorder.[17]
• Common Adverse Reactions: The most common adverse reactions (≥20% incidence) reflect its systemic toxicity and include leukopenia (low white blood cells), diarrhea, neutropenia, proteinuria, increased liver enzymes, stomatitis (mouth sores), fatigue, and thrombocytopenia (low platelets).[1]

Table 5: Comparative Summary of Key Safety Information: Eylea® vs. Zaltrap®

Safety Parameter	Eylea® (Ophthalmic Formulation)	Zaltrap® (Systemic Formulation)
Boxed Warning	None	Yes: Hemorrhage, Gastrointestinal Perforation, Compromised Wound Healing
Contraindications	Active ocular infection, active intraocular inflammation, hypersensitivity	None
Key Warnings	Endophthalmitis, retinal detachment, increased IOP, rare ATEs, retinal vasculitis	Fistula formation, severe hypertension, ATEs, proteinuria/nephrotic syndrome, neutropenia, severe diarrhea, RPLS
Common Adverse Reactions (≥5-20%)	Conjunctival hemorrhage, eye pain, cataract, vitreous floaters, increased IOP	Leukopenia, diarrhea, neutropenia, proteinuria, stomatitis, fatigue, hypertension

Regulatory, Commercial, and Future Landscape

The commercial trajectory of Aflibercept is a story of strategic partnerships, successful clinical development in ophthalmology, and a challenging path in oncology, now culminating in a new era of biosimilar competition.

A. Development and Partnership History

Aflibercept was discovered and developed by Regeneron Pharmaceuticals.[5] Recognizing the molecule's potential in different therapeutic areas and the immense resources required for global development, Regeneron forged key strategic alliances:

• Oncology: In 2003, Regeneron partnered with Aventis (which later became part of Sanofi) to co-develop Aflibercept for cancer indications. Clinical testing in cancer began in 2001.[5] Under the agreement, the companies share global profits from Zaltrap®.[48]
• Ophthalmology: After beginning to test a locally delivered formulation for eye diseases in 2004, Regeneron entered into a collaboration with Bayer in 2006. Under this agreement, Regeneron retains exclusive commercial rights to Eylea® in the United States, while Bayer holds exclusive rights for all territories outside the U.S., with profits from these sales being shared between the two companies.[5]

B. Global Regulatory Milestones

The regulatory journey of Aflibercept saw rapid and expanding success for Eylea®, contrasted with a more limited approval for Zaltrap®.

• November 18, 2011: The U.S. FDA grants its first approval for Eylea® for the treatment of nAMD.[7]
• August 3, 2012: The U.S. FDA approves Zaltrap® (ziv-aflibercept) in combination with FOLFIRI for second-line mCRC, following a Priority Review.[5]
• November 2012: The European Medicines Agency (EMA) authorizes Eylea® for wet AMD.[5]
• February 2013: The EMA authorizes Zaltrap® for second-line mCRC.[5]
• 2014-2019: Eylea® receives a series of label expansions from the FDA for Macular Edema following RVO (2014), DME (2014), and Diabetic Retinopathy (2015, expanded in 2019).[5]
• February 8, 2023: Eylea® receives a landmark FDA approval as the first pharmacologic treatment for Retinopathy of Prematurity (ROP).[1]
• August 2023: The FDA approves the high-dose formulation, Eylea HD® (8 mg), for nAMD, DME, and DR, offering extended dosing intervals.[5]

C. The Era of Biosimilars

The year 2024 marked a pivotal turning point for the Aflibercept franchise as it began to face biosimilar competition.

• Market Exclusivity Expiration: Regeneron's key regulatory exclusivity for the original 2 mg Eylea® formulation expired on May 18, 2024.[66]
• First Approvals: Just two days later, on May 20, 2024, the FDA approved the first two biosimilars to Eylea®: Yesafili (aflibercept-jbvf) from Biocon Biologics and Opuviz (aflibercept-yszy) from Samsung Bioepis.[68] Several other biosimilars, including Ahzantive (aflibercept-mrbb) and Enzeevu (aflibercept-abzv), have since been approved.[5]
• Interchangeability: Critically, both Yesafili and Opuviz were approved with an interchangeable designation. This is a significant regulatory achievement, as it allows a pharmacist to substitute the interchangeable biosimilar for the reference product (Eylea®) without needing to consult the prescribing physician, subject to state laws. This is expected to accelerate uptake and facilitate easier access to lower-cost alternatives.[68]
• Patent Litigation: Despite these approvals, the timing of market launch for these biosimilars remains uncertain. Regeneron has actively defended its intellectual property, filing patent infringement lawsuits against multiple biosimilar developers, including Biocon, Samsung Bioepis, Amgen, and Celltrion. These legal battles over formulation and manufacturing patents are a key barrier and will likely result in settlement agreements that dictate the precise launch dates for each competitor.[66]

D. Future Directions

Regeneron's strategy to navigate the post-exclusivity landscape is clear and multi-pronged.

• The Eylea HD® Defense: The primary strategy is to convert the market from the 2 mg formulation to the newer, patent-protected 8 mg Eylea HD®. By offering a superior clinical profile with longer dosing intervals, the company aims to retain market share and defend against erosion from 2 mg biosimilars.[30]
• Lifecycle Management: The company continues to invest in expanding the utility of Eylea HD®, with a supplemental Biologics License Application (sBLA) under FDA review for the treatment of RVO and for adding a more frequent monthly dosing option to the label for all approved indications, providing physicians with maximum flexibility.[72]

Table 6: Approved Aflibercept Biosimilars and Regulatory Status (as of mid-2024)

Biosimilar Name	Non-proprietary Name	Manufacturer	FDA Approval Date	EMA Approval Date	Interchangeable (US)
Yesafili	aflibercept-jbvf	Biocon Biologics / Viatris	May 20, 2024	Sep 2023	Yes
Opuviz	aflibercept-yszy	Samsung Bioepis	May 20, 2024	N/A	Yes
Ahzantive	aflibercept-mrbb	Sandoz	June 2024	N/A	Yes
Enzeevu	aflibercept-abzv	Amgen	Aug 2024	N/A	Yes
Pavblu	aflibercept-ayyh	Teva	Aug 2024	N/A	Yes

Sources: [5]

Synthesis and Expert Recommendations

Aflibercept stands as a testament to the power of targeted biologic engineering. Its molecular design as a high-affinity VEGF trap is not merely an academic curiosity; it is the scientific foundation of a clinical and commercial success story. The molecule's potent, broad-spectrum, and sustained neutralization of key angiogenic factors translates directly into its primary clinical advantage: a longer duration of action that reduces treatment burden. This single attribute has propelled Eylea® to a dominant position in the multi-billion-dollar global ophthalmology market. Yet, this same potency is a double-edged sword. When delivered systemically at high doses, the profound inhibition of a fundamental biological pathway results in the severe, multi-system toxicities that have relegated Zaltrap® to a niche, second-line role in oncology. Aflibercept is, in essence, two different drugs derived from one molecule, their fates dictated by the principles of dose, delivery, and therapeutic index.

Actionable Insights for Clinicians

• For the Ophthalmologist: The choice among anti-VEGF agents remains a complex balance of efficacy, treatment burden, and cost. Aflibercept's principal value proposition is the ability to extend treatment intervals, which is highly valued by patients with chronic diseases requiring lifelong therapy. The data from DRCR.net Protocol T suggests that in DME, a stratified approach may be optimal, reserving Aflibercept for patients with more significant initial vision loss where its superior efficacy is most pronounced. For patients with milder disease, the clinical equivalence of the three main agents makes cost a more prominent factor. The advent of Eylea HD® further solidifies the extended-dosing paradigm as the primary differentiator for the Aflibercept franchise.
• For the Oncologist: Zaltrap® is a valid, albeit challenging, therapeutic option. Its established efficacy in the second-line treatment of mCRC, particularly its activity in patients who have already progressed on bevacizumab, gives it a clear place in the treatment algorithm. However, its use demands vigilant monitoring and proactive management of its significant toxicities, especially hemorrhage, GI perforation, and hypertension. The decision to use Zaltrap® must involve a careful weighing of its modest survival benefit against its substantial risk profile and a thorough discussion of these risks with the patient.

Forward-Looking Perspective

The Aflibercept franchise is at a watershed moment. The originator's future now hinges on its ability to successfully execute a two-part strategy: first, to convert a significant portion of the market to the patent-protected, longer-acting Eylea HD® formulation, and second, to use ongoing patent litigation to manage the timing and pace of biosimilar entry. The future of the entire intravitreal anti-VEGF market will be defined by the new equilibrium struck between originator lifecycle management, the market penetration and pricing of interchangeable biosimilars, and the ongoing innovation of next-generation therapies promising even longer durations of effect. For patients and healthcare systems, this new era of competition holds the promise of increased access and reduced costs for these sight-saving therapies.

Works cited

1. Aflibercept: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 16, 2025, https://go.drugbank.com/drugs/DB08885
2. CAS 862111-32-8 Aflibercept - BOC Sciences, accessed July 16, 2025, https://www.bocsci.com/aflibercept-cas-862111-32-8-item-244884.html
3. Aflibercept - EyeWiki, accessed July 16, 2025, https://eyewiki.org/Aflibercept
4. Aflibercept—a Decoy VEGF Receptor - PMC, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5145308/
5. Aflibercept - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Aflibercept
6. Aflibercept - PubChem, accessed July 16, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Aflibercept
7. 862111-32-8 | CAS DataBase - ChemicalBook, accessed July 16, 2025, https://www.chemicalbook.com/CASEN_862111-32-8.htm
8. Fusion proteins: Aflibercept (VEGF Trap-Eye) | Request PDF - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/283262650_Fusion_proteins_Aflibercept_VEGF_Trap-Eye
9. Aflibercept - StatPearls - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK582136/
10. www.ncbi.nlm.nih.gov, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK582136/#:~:text=It%20is%20in%20the%20vascular,for%20angiogenesis%20and%20vascular%20leakage.
11. Eye Injections for Retinal Diseases | EYLEA® (aflibercept) Injection, accessed July 16, 2025, https://eylea.us/s/
12. Ziv-Aflibercept - NCI, accessed July 16, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/ziv-aflibercept
13. Aflibercept - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK500828/
14. Fusion Proteins: Aflibercept (VEGF Trap-Eye) - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/26501481/
15. Aflibercept - brand name list from Drugs.com, accessed July 16, 2025, https://www.drugs.com/ingredient/aflibercept.html
16. Aflibercept Intravitreal: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 16, 2025, https://www.rxlist.com/aflibercept_intravitreal/generic-drug.htm
17. ZALTRAP® (ziv-aflibercept): Metastatic Colorectal Cancer (mCRC) Treatment, accessed July 16, 2025, https://www.zaltrap.com/
18. en.wikipedia.org, accessed July 16, 2025, https://en.wikipedia.org/wiki/Aflibercept#:~:text=Aflibercept%2C%20sold%20under%20the%20brand,was%20developed%20by%20Regeneron%20Pharmaceuticals.
19. Zaltrap (ziv-aflibercept) FDA Approval History - Drugs.com, accessed July 16, 2025, https://www.drugs.com/history/zaltrap.html
20. aflibercept | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 16, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=6786
21. Efficient Expression of Functionally Active Aflibercept with Designed N-glycans - MDPI, accessed July 16, 2025, https://www.mdpi.com/2073-4468/13/2/29
22. Aflibercept (VEGF Trap) | VEGFR Inhibitor - MedchemExpress.com, accessed July 16, 2025, https://www.medchemexpress.com/aflibercept-vegf-trap.html
23. Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases | BMJ Open Ophthalmology, accessed July 16, 2025, https://bmjophth.bmj.com/content/4/1/e000185
24. Aflibercept Biosimilar, Research Grade Zaltrap / Eylea Biosimilar, VEGF Receptor - Fc Fusion Protein - Syd Labs, accessed July 16, 2025, https://www.sydlabs.com/aflibercept-biosimilar-p15446.htm
25. Eylea 40mg/ml solution for injection in a vial - Summary of Product Characteristics (SmPC) - (emc) | 2879, accessed July 16, 2025, https://www.medicines.org.uk/emc/product/2879/smpc
26. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, accessed July 16, 2025, https://www.bayer.com/sites/default/files/eylea-8mg-smpc-jan-2024-0.pdf
27. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD | British Journal of Ophthalmology, accessed July 16, 2025, https://bjo.bmj.com/content/98/12/1636
28. Intravitreal administration - Wikipedia, accessed July 16, 2025, https://en.wikipedia.org/wiki/Intravitreal_administration
29. What is the mechanism of Aflibercept? - Patsnap Synapse, accessed July 16, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-aflibercept
30. Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals | Regeneron Pharmaceuticals Inc., accessed July 16, 2025, https://investor.regeneron.com/news-releases/news-release-details/three-year-results-eylea-hdr-aflibercept-injection-8-mg-patients/
31. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration - PMC - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6723750/
32. Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11764841/
33. Eylea (aflibercept) FDA Approval History - Drugs.com, accessed July 16, 2025, https://www.drugs.com/history/eylea.html
34. RESULTS - Aflibercept (Eylea) - NCBI Bookshelf, accessed July 16, 2025, https://www.ncbi.nlm.nih.gov/books/NBK349590/
35. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/23084240/
36. Aflibercept Monograph for Professionals - Drugs.com, accessed July 16, 2025, https://www.drugs.com/monograph/aflibercept.html
37. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3595183/
38. Wet AMD Clinical Trial Results | EYLEA® HD (aflibercept) Injection, accessed July 16, 2025, https://eyleahcp.us/s/eyleahd/wet-amd-anatomy-outcomes
39. Two-Year Results From Phase 3 VISTA Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision, accessed July 16, 2025, https://newsroom.regeneron.com/news-releases/news-release-details/two-year-results-phase-3-vista-trial-eylear-aflibercept
40. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial - PMC - PubMed Central, accessed July 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4877252/
41. EYLEA® (aflibercept) injection, for intravitreal use - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125387s087lbl.pdf
42. BLA 125387/S-051 Page 4 - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125387s051lbl.pdf
43. Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment. - ASCO, accessed July 16, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT105830
44. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/24140268/
45. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed - NICE, accessed July 16, 2025, https://www.nice.org.uk/guidance/ta307/documents/colorectal-cancer-metastatic-aflibercept-final-appraisal-determination3
46. VELOUR trial in second-line treatment of metastatic colorectal cancer - ecancer, accessed July 16, 2025, https://ecancer.org/en/news/1909-velour-trial-in-second-line-treatment-of-metastatic-colorectal-cancer
47. Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment. - ASCO Publications, accessed July 16, 2025, https://ascopubs.org/doi/10.1200/jco.2013.31.4_suppl.451
48. U.S. FDA Approves ZALTRAP® (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer | Regeneron Pharmaceuticals Inc., accessed July 16, 2025, https://investor.regeneron.com/news-releases/news-release-details/us-fda-approves-zaltrapr-ziv-aflibercept-after-priority-review/
49. ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients - Regeneron Investor Relations, accessed July 16, 2025, https://newsroom.regeneron.com/news-releases/news-release-details/zaltraptm-aflibercept-significantly-improved-survival-previously/
50. Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting, accessed July 16, 2025, https://investor.regeneron.com/news-releases/news-release-details/results-vegf-trap-aflibercept-highlighted-asco-2007-annual/
51. Aflibercept - Bayer/Regeneron Pharmaceuticals/Sanofi - AdisInsight - Springer, accessed July 16, 2025, https://adisinsight.springer.com/drugs/800013847
52. Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept), accessed July 16, 2025, https://investor.regeneron.com/news-releases/news-release-details/sanofi-and-regeneron-announce-regulatory-and-clinical-update/
53. Reference ID: 31694 - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf
54. North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. - ASCO Publications, accessed July 16, 2025, https://ascopubs.org/doi/10.1200/jco.2013.31.15_suppl.e14528
55. (PDF) Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study - ResearchGate, accessed July 16, 2025, https://www.researchgate.net/publication/351111099_Cost_Effectiveness_of_Ranibizumab_vs_Aflibercept_vs_Bevacizumab_for_the_Treatment_of_Macular_Oedema_Due_to_Central_Retinal_Vein_Occlusion_The_LEAVO_Study
56. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective | PLOS One, accessed July 16, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197670
57. Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study - PubMed, accessed July 16, 2025, https://pubmed.ncbi.nlm.nih.gov/33900585/
58. Full article: Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data, accessed July 16, 2025, https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1666855
59. Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a US perspective: analysis of 2-year Protocol T data - Taylor & Francis Online, accessed July 16, 2025, https://www.tandfonline.com/doi/abs/10.1080/13696998.2019.1666855
60. EYLEA Prescribing Information - Regeneron, accessed July 16, 2025, https://www.regeneron.com/downloads/eylea_fpi.pdf
61. EYLEA HD (aflibercept) injection, for intravitreal use - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761355s006lbl.pdf
62. BLA 125387/S-061 Page 4 This label may not be the latest approved by FDA. For current labeling information, please visit https: - accessdata.fda.gov, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125387s061lbl.pdf
63. Eylea | European Medicines Agency (EMA), accessed July 16, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/eylea
64. ZALTRAP® (ziv-aflibercept) injection, for intravenous use Prescribing Information - Sanofi U.S., accessed July 16, 2025, https://products.sanofi.us/zaltrap/zaltrap.html
65. 1 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatf, accessed July 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125418s045lbl.pdf
66. Updates on Aflibercept Biosimilar Approvals and BPCIA Litigation | Insights & Resources, accessed July 16, 2025, https://www.goodwinlaw.com/en/insights/blogs/2024/06/updates-on-aflibercept-biosimilar-approvals-and-bpcia-litigation
67. Aflibercept biosimilars - so near, yet so far - Taylor and Francis, accessed July 16, 2025, https://www.tandfonline.com/doi/full/10.1080/14712598.2025.2482663
68. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions, accessed July 16, 2025, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-eylea-treat-macular-degeneration-and-other-eye
69. Samsung Bioepis & Biocon Receive First US Approvals of Aflibercept Biosimilars with Interchangeability | Pearce IP, accessed July 16, 2025, https://www.pearceip.law/2024/05/20/samsung-bioepis-biocon-receive-first-us-approvals-of-aflibercept-biosimilars-with-interchangeability/
70. FDA Approves First Eylea Biosimilars, accessed July 16, 2025, https://www.centerforbiosimilars.com/view/fda-approves-first-eylea-biosimilars
71. FDA Approves First Biosimilars to Eylea - Retinal Physician, accessed July 16, 2025, https://www.retinalphysician.com/issues/2024/june/fda-approves-first-biosimilars-to-eylea/
72. Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA - Ophthalmology Times, accessed July 16, 2025, https://www.ophthalmologytimes.com/view/aflibercept-applications-for-dosing-duration-and-additional-indications-pending-decision-with-fda-and-ema
73. EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications, accessed July 16, 2025, https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-sbla-accepted-fda-priority/